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Autophagy is a catabolic process responsible for the degradation and recycling of long-lived proteins and organelles by lysosomes.
This degradative pathway sustains cell survival during nutrient deprivation, but in some circumstances, autophagy leads to cell
death. Thereby, autophagy can serve as tumor suppressor, as the reduction in autophagic capacity causes malignant transformation
and spontaneous tumors. On the other hand, this process also functions as a protective cell-survival mechanism against
environmental stress causing resistance to antineoplastic therapies. Although autophagy inhibition, combined with anticancer
agents, could be therapeutically beneficial in some cases, autophagy induction by itself could lead to cell death in some apoptosis-
resistant cancers, indicating that autophagy induction may also be used as a therapy. This paper summarizes the most important
findings described in the literature about autophagy and also discusses the importance of this process in clinical settings.
1. Autophagy: Basic Concepts
Autophagy is the primary intracellular catabolic process
responsible for long-lived proteins and organelles degrada-
tion and recycling, whereas the ubiquitin/proteosome system
is the major cellular pathway responsible for short-lived
proteins degradation [1]. Autophagy is an evolutionarily
conserved mechanism throughout macromolecules, ribo-
somes, and organelles are degraded.
Initial steps include vesicle nucleation (isolation of
the membrane), vesicle elongation, and completion of the
double-membrane vesicle [2]. In autophagy, the cytosolic
elements that must be degraded are sequestrated by an
isolating double-membrane vesicle of nonlysosomal origin
that is sealed, creating an autophagic vacuole or autophago-
some. Fusion of lysosomes with autophagosomes provides
the enzymes required for degradation of sequestrated com-
ponents [3]. The initial phagophores are formed from
the endoplasmic reticulum, and they act surrounding and
packing organelles to form autophagosomes [4] (Figure 1).
Recently, autophagy emerged as a multifunctional path-
way activated in response to microenvironmental stress,
intracellular damage caused by hypoxia, chemotherapeutic
agents, virus infections, and toxins. Autophagy may also have
a role in cell death, as cancer cells often develop mutations
that confer resistance to apoptosis. Nonapoptotic forms of
programmed cell death (PCD) might be targeted for novel
approaches [5, 6].
2. Physiological Functions of
Autophagy Process
Autophagy is considered a physiological mechanism that
may serve for temporary cell survival and is triggered by
starvation, such as amino acid and nutrient deprivation,
hypoxia, and metabolic stress [3].
Recent studies have demonstrated the existence of a
nonapoptotic form of programmed death called autophagic
cell death, which is now considered as programmed cell death
(PCD II). Although autophagy was initially described as a
protective mechanism allowing cell survival and generating
nutrients and energy, other studies have demonstrated that
continuous stress can also promote PCD II [2].





Figure 1: Diﬀerent mechanisms to recycle molecules and organelles in the eukaryotic cell. Eukaryotes have two major protein degradation
systems within cells. One is the ubiquitin-proteasome system, which accounts for the selective degradation of most short-lived proteins. The
other is the autophagy, the primary means for the degradation of cytoplasmic constituents in the lysosome.
2.1. Role of Autophagy in Normal Mammary Gland Develop-
ment. Several works have proved that autophagy is impli-
cated in normal mammary gland development.
In mammalian, the mammary gland expresses its
maximum growth potential maturity after pregnancy and
during lactation. The cycle of proliferation-diﬀerentiation-
regression is repeated at each gestation and can be repro-
duced in culture systems in vitro. A deeper understanding
of how growth and diﬀerentiation of the mammary tissue
are regulated can complement the knowledge of the devel-
opmental process as well as the treatment and prevention of
mammary cancers [7].
PCD is an essential physiological process operating at
all stages of mammary gland remodeling. During mammary
gland involution, the extracellular matrix (ECM) and alveo-
lar basement membrane are degraded. Also, the alveoli lose
their structural integrity, and massive death of mammary
epithelial cells is observed. PCD I (apoptosis) is responsible
for cell loss during mammary gland involution [8, 9].
However, there is a lot of evidence suggesting that not only
PCD I, but also PCD II is observed in mammary epithelial
cells.
In vitro and in vivo studies of bovine mammary gland
physiology have revealed that an enhanced process of
autophagy is observed at the end of lactation and during dry
periods [10, 11]. It is manifested by the increased expression
of Beclin 1 and the higher number of cells with typical
morphological features of autophagy. Furthermore, 3D
model of bovinemammary epithelial cells grown onMatrigel
showed that during the development and diﬀerentiation of
mammary acini, the level of membrane-boundmicrotubule-
associated protein chain 3 (LC3) was increased [12, 13]. This
protein is a well-known autophagy marker.
3. AutophagyMarker
The development of targeted small molecule inhibitors, like
those used for PI3K-AKT-mTOR pathway, has presented
a molecular link between the disruption of this signaling
cascade and the autophagy process. The cellular consequence
of stimulating or inhibiting autophagy in cancer cells is not
completely understood, so it is important that this process
be monitored, along with antiproliferative and apoptotic
biomarkers, in the preclinical setting.
LC3 is considered as a specific autophagy marker [14].
After the synthesis of LC3, this molecule is cleaved to form
LC3-I, and upon induction of autophagy, LC3-I is conjugated
to the lipid phosphatidylethanolamine to form LC3-II, which
is tightly bound to the membrane of the autophagosome
[15]. Immunoblotting assessment of LC3 expression is an
easy method to predict autophagic activity of mammalian
cells, because the amount of LC3-II correlates with the
number of autophagosomes [13, 16–18]. The product of
autophagic conversion of LC3, LC3-II, tightly associates with
the autophagosome membrane and migrates faster than
LC3-I on SDS-PAGE. Therefore, LC3 immunoblotting may
detect two bands: LC3-I with an apparent mobility of 18 kDa
and LC3-II with an apparent mobility of 16 kDa.
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4. Controversial Role of Autophagy in
Malignant Transformation
Autophagy could be associated with various pathological
conditions including, cardiomyopathy, muscular diseases,
neurodegenerative disorders, and cancer.
4.1. Autophagy as a Tumor-Suppressor Mechanism. Studies in
diﬀerent cells lines have shown that cancer cells express lower
levels of the autophagy-related proteins LC3-II and Beclin 1
than normal epithelial cells [19, 20]. Besides, while heterozy-
gous disruption of BECN1 gene promotes tumor develop-
ment [19], the overexpression inhibits tumorigenesis [21],
supporting the idea that defective autophagy or autophagy
inhibition plays a role in malignant transformation. BECN1
gene is deleted in about 50% of breast cancers [21, 22]. In
addition, reduced expression of Beclin1 has been reported
in other types of cancers such as colon and brain tumors
[23, 24]. Overall, the data suggest that a defective autophagic
process is clearly linked to cancer development.
The most important evidence linking dysfunctional
autophagy and cancer comes from studies demonstrating
that autophagy inhibition in mice, by disruption of BECN1,
increases cellular proliferation as well as mammary hyper-
plasia and accelerates tumor development. In addition,
transfection of MCF-7 breast cancer cells, that express low
levels of Beclin 1, with BECN1 gene, inhibits growth and
tumor formation [21]. These results suggest that Beclin 1 is a
haploinsuﬃcient tumor suppressor and defective autophagy
may be critical for cells malignant transformation [19].
In contrast to apoptosis, PCD II, in general, is caspase
independent, does not involve classic DNA laddering, and is
believed to be a result of an extensive autophagic degradation
of intracellular content [25]. Studies also suggest that
apoptosis and autophagy are linked by eﬀectors proteins
(e.g., Bcl-2, Bcl-XL, Mcl-1, ATG5, and p53) and common
pathways (e.g., PI3K/Akt/mTOR, NFκB, and ERK) [5, 26,
27]. For example, p53 activation triggers starvation response
in primary mouse embryonic fibroblasts, which is marked
by activation of AMPK (AMP-activated kinase) that inhibits
mTOR pathway. In other tissues and cells, p53 may commu-
nicate with mTOR pathway by the upregulation of the PTEN
and TSC2 genes [28].
There is evidence that autophagy may function as a PCD
II in cancer cells in which apoptosis is defective or hard
to induce [29]. Therefore, it is reasonable to propose that
the induction of autophagic cell death may be used as a
therapeutic strategy for cancer treatment.
4.2. Autophagy as a Survival and Drugs-Resistance Mech-
anism. The physiological function of autophagy is related
to the maintenance of cellular homeostasis under cellular
stress. Utilizing autophagy as a survival mechanism in the
severe tumor microenvironment, which is highly hypoxic
and acidic, may favor the development of cancer cells.
It was observed that a high number of antineoplastic
therapies, radiation therapy, chemotherapy (e.g., doxo-
rubicin, temozolomide, and etoposide), histone deacety-
lase inhibitors, arsenic trioxide, TNFα, IFNγ, imatinib,
rapamycin, and antiestrogen hormonal therapy (e.g., tamox-
ifen) induce autophagy, and this induction act as a protective
and prosurvival mechanism in human cancer cell lines [20].
In fact, the therapeutic eﬃcacy of these agents can be
increased if autophagy is inhibited [30–35]. Other studies
have shown that a tumor necrosis factor (TNF) family
ligand-tumor necrosis factor-related apoptosis-inducing lig-
and (TRAIL), induces autophagy in epithelial cells and
that TRAIL inhibition promotes luminal filling, when it
is combined with Bcl-xL-mediated inhibition of apoptosis
[36].
Altogether, disruption of autophagy is involved in diverse
human diseases including cancer. In particular, the reg-
ulation of autophagy in cancer cells is complex, since it
can enhance tumor cell survival in response to certain
stresses, but it can also act to suppress the initiation of
tumor growth. In contrast to its protective role, inhibition
of autophagy through specific gene inactivation can promote
tumorigenesis [2].
5. Autophagy as a Therapeutic Target in
Cancer Patients
Autophagy, which could be either cytoprotective or cytotoxic,
is often observed in tumor cells in response to chemotherapy
[49] (Table 1).
Mutations or allelic loss of Beclin 1 is frequently found in
breast, ovarian, and prostate cancer [9, 10]. Beclin 1 provided
the first connection between cancer and autophagy [2]. It
has been suggested that autophagy plays an important role
in chemoresistance of cancer to some therapeutic agents that
typically induce an apoptotic response [39].
5.1. Role of Autophagy in Resistance to Therapy
5.1.1. Autophagy in Breast Cancer Treatment: Endocrine
Therapy and Endocrine Resistance. Endocrine therapy is
administered as an antiestrogen (AE) like Tamoxifen (TAM)
or Fulvestrant (FAS; Faslodex; ICI 182,780) or as aromatase
inhibitor (AI) such as Letrozole or Exemestane. It is less
toxic and potentially more eﬀective therapy in management
of hormone-dependent breast cancers. Antiestrogens, and
TAM in particular, have been the “gold standard” first-
line endocrine therapy for over 30 years [50]. It is likely
that the clinical experience with this drug exceeds 15
million patient years [51]. Moreover, TAM is the only single
agent with demonstrated eﬃcacy in both premenopausal
and postmenopausal women with invasive breast cancer.
Unfortunately, until nowadays, the inability of endocrine
therapies to cure many women with ER+ disease remains.
The precise mechanism by which breast cancer cells
die following estrogen withdrawal (or AI treatment) or AE
treatment is unclear. For example breast cancer cells respond
to AEs and to estrogen withdrawal even if they have a
mutated p53 [52, 53]. Although cell death is one of the
apoptosis endpoints, there are earlier events initiated by
autophagy signals that could be explaining these treatment
responses [53].
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Table 1: Chemotherapeutic agents involved in autophagy induc-
tion.





AMPK Metformin [39, 40]
Bcr-Abl Imatinib [41]
BNIP3 Arsenic trioxide [42]










Autophagy has been implicated by the induction of
this mechanism in response to endocrine therapy. Recent
studies showed that endocrine therapy modifies the number
of autophagosomes, increases LC3 protein cleavage, and
reduces expression of p62 [54]. Consistent with other
reports, PCD II is associated with the growth inhibitory
eﬀects of endocrine therapy in breast cancer cells [32, 55, 56].
It remains unclear whether autophagy or apoptosis
dominates as the cell-deathmechanism or whether this varies
among diﬀerent breast cancer cells.
While there is currently no definitive understanding of
the primary cell-death mechanisms either in experimental
models or breast tumors in women about the relative
importance of endocrine therapy-induced changes in pro-
liferation, there are potentially important implications for
the underlying biology of the cancer cells. If the primary
driver of response as seen in tumor shrinkage is a reduction
in proliferation, this will leave many cells alive and still
metabolically active. Surviving cells have the ability to adapt
to the endocrine-induced stress and eventually overcome the
proliferative blockade and grow so that, they will become
resistant [57–59]. It is quite possible that autophagy allows
breast cancer cells to adapt to endocrine-induced stress
and survive. Evidence showed that inhibition of autophagy
sensitizes breast cancer cells to TAM [32].
5.1.2. The Role of Autophagy in Bortezomib Treatment against
Breast Cancer. The 26S proteasomes are multicatalytic pro-
tease complexes consisting of a 20S catalytic core and a
regulator 19S subunit responsible for most nonlysosomal
intracellular degradation [60]. The dipeptide boronic acid
Bortezomib is a selective and potent inhibitor of the
26S proteasome that reversibly inhibits the proteasomal
chymotrypsin-like activity [60, 61].
The inhibition of the 26S proteasome by Bortezomib
may lead to the accumulation and aggregation of misfolded
proteins in the endoplasmic reticulum lumen resulting
in the activation of an unfolded protein response (UPR)
through the action of three key endoplasmic reticulum-
resident transmembrane proteins, pERK, IRE1, and ATF6
[62–64]. The activated protein pERK is a member of a
family of protein kinases that phosphorylates the subunit of
the cytosolic eukaryotic translation initiation factor eIF2a,
resulting in a reduced global protein synthesis and in a pref-
erential translation of selected mRNAs including activating
transcription factor 4 (ATF4) [63, 64]. Some reports have
identified endoplasmic reticulum stress and the eIF2a/pERK
pathway as potent inducers of macroautophagy where it
promotes cell survival [65–67].
A recent study in MCF7 cell line showed that during
Bortezomib treatment, LC3B protein and mRNA levels
increased significantly in a dose and time-dependent man-
ner. The increase of autophagy in Bortezomib-treated cells
was dependent on upregulation of LC3B by ATF4 [68]. In
addition, MCF7 cells transfected with RNAi specific to LC3B,
ATF4, or pERKweremore sensitive to Bortezomib treatment.
Furthermore, the loss of LC3B or ATF4 was associated with
a significant increase in dead cells staining for both Annexin
V and propidium iodide after 48 and 72 hours of treatment
[68].
From a clinical point of view, it would be an attractive
possibility to target autophagy to enhance the response of
breast cancer to Bortezomib and sensitize to environmental
stress that normally occurs in solid tumors.
However, clinical experience with Bortezomib has shown
limited activity against breast cancer when used as a single
agent [61].
5.1.3. The Role of Autophagy in Trastuzumab Treatment
against Breast Cancer. Trastuzumab (Tzb andHerceptin) was
the first immunotherapeutic drug for the treatment of breast
carcinomas overexpressing the HER2 (erbB-2) oncogene
that was successful [69–73]; however, the mechanisms that
could explain de novo and acquired resistance to anti-HER2
monoclonal are not well understood. Proposed mechanisms
for innate or acquired resistance to Tzb include steric
inhibition of Tzb binding to the extracellular domain (ECD)
of the HER2 tyrosine kinase receptor imposed by other
extracellular factors such as the glycoproteinmucin 4 (MUC-
4) [74, 75].
Recent work showed that Tzb-resistant HER2-positive
breast cancer cells (SKBR3 cell line) exhibit increased
basal autophagy through an increase in LC3-II expression
compared to Tzb-naı¨ve SKBR3 parental cells, suggesting
that acquired Tzb autoresistance of Tzb-conditioned cells
is accompanied by increased autophagy. Furthermore, inhi-
bition of formation of preautophagosomal structure upon
treatment with 3-methyladenime (3-MA), a pharmacolog-
ical inhibitor of autophagy, notably reduced cell viability
in Tzb-resistant HER2-positive breast cancer cells but not
in Tzb-naı¨ve SKBR3 parental cells [76]. To provide addi-
tional evidence that autophagy plays a critical survival role
in enabling Tzb-insensitive high-rates of cell proliferation
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in Tzb-refractory cells, the potent and highly sequence-
specific mechanism of RNA interference (RNAi) was used to
block LC3-dependent autophagosome formation. This assay
avoided any oﬀ-target side eﬀects that may confound inter-
pretation of the results obtained with autophagy inhibitors,
showed that TzbR cells were extremely fragile [76]. These
findings, altogether, clearly established that hyperactivation
of basal autophagy plays an essential survival role in Tzb-
refractory TzbR cells rechallenged with Tzb. Therefore,
the Tzb combination with autophagy inhibitors may be
a promising strategy in patients resistant to therapy with
Trastuzumab.
5.2. Role of Autophagy in the Enhancement of the Inhibitory
Eﬀect of Breast Cancer Treatments
5.2.1. Autophagy Enhances the Inhibitory Eﬀect of Paclitaxel
through ARHI Expression. ARHI encodes a small GTP-
binding protein belonging to the Ras/Rap superfamily, which
has the characteristics of a tumor suppressor gene in ovarian
and breast cancers, despite sharing 54–59% homology with
Ras proto-oncogenes [77], ARHI is expressed in normal
breast epithelial cells, but in more than 70% of breast
cancers, it is dramatically downregulated. Loss of ARHI
expression has been linked to tumor progression from in
situ to invasive cancer [78]. Paclitaxel, a cytotoxic drug, can
inhibit cancer cell growth by inducing apoptosis and G2/M
cell-cycle arrest. TSA, anHDAC inhibitor, can activate several
tumor suppressor genes and induces autophagy.
Recent evidence showed that ARHI induces autophagy in
breast cancer cells. SKBR3 andMDA-MB231 cells, expressing
low levels of endogenous ARHI transfected with ARHI, had
an increase of LC3 punctate number, which represent the
accumulation of LC3 membrane-bound form on autophagic
vesicles. Furthermore, it has been observed that TSA treat-
ment enhanced autophagy, but transfection with siRNA-
ARHI blocked the eﬀects of TSA, demonstrating that ARHI
is essential for autophagy induction [79].
Other results from the same group showed that TSA
greatly enhanced the inhibitory eﬀect of paclitaxel and
tumors treated with a combination of ARHI and paclitaxel
grew significantly more slowly than controls, whereas the
individual treatments did not significantly inhibit tumor
growth [79].
6. Conclusion and Perspectives
We can conclude that autophagy regulation may provide
a useful tool to prevent cancer development, limit tumor
progression, and increase the eﬃciency of cancer treatment.
This autophagy regulation has to be context dependent, since
an autophagy process increased may be necessary to prevent
tumor development in individuals at high risk of cancer. But
autophagy activity must be reduced when tumor is already
established and subjected to the environmental stresses
associated with limited angiogenesis, nutrient deprivation,
and hypoxia.
Understanding the signaling pathways involved in
autophagy regulation represents a new direction in the
development of anticancer therapies. However, the proteins
and traﬃcking mechanisms involved in the autophagosomal
maturation step are not completely understood.
The eﬀectiveness of chemotherapeutics is diminished by
the fact that they induce toxicity to both normal and cancer
cells. Many targeted therapies studies have been conducted to
new drugs development with higher therapeutic index. Cur-
rently, signaling transduction pathways, tumor angiogenesis,
and malignant stem cells are considered prime targets for
new therapeutics development.
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